Jeffrey A. Meckler
Mr. Meckler joined our Board in April 2017 as Vice Chairman and was appointed Chief Executive Officer in July 2017. Mr. Meckler brings more than 25 years of financial and healthcare experience, having held a variety of senior leadership roles in both large and small biopharma companies. Mr. Meckler started his career in life sciences at Pfizer, Inc. During his 17 years at Pfizer, Mr. Meckler rose through a series of positions eventually becoming a member of the Corporate Finance Leadership Team overseeing a number of acquisition and divestitures. Most recently, Mr. Meckler was the CEO of Cocrystal Pharma, transforming it from a research company into a clinical and development company. Additionally, Mr. Meckler led QLT, Inc., Cypress Bioscience, Inc. and Retrophin, Inc. through transformational times. Mr. Meckler has served on the board of a number of private and public companies and is currently a director and former Chairman of Retrophin. Mr. Meckler holds a B.S. in Industrial Management and a M.S. in Industrial Administration from the Tepper School of Business at Carnegie Mellon University. Additionally, he received his J.D. from Fordham University’s School of Law.
Nadav Navon, Ph.D.
Dr. Nadav Navon has been with us since March 2006 and has served as our COO since July 2017. Before that he served as our Executive Vice President of Research & Development and Operations since March 2015. Prior to his service with us, Dr. Navon headed the analytical and quality assurance operations at Sharon Laboratories Ltd., a chemical company that develops and manufactures raw materials for the pharmaceutical, cosmetic and food industries, from 2001 to 2006. Prior to that, Dr. Navon led a number of research and development projects in the Negev’s Nuclear Research Center. Dr. Navon has a Ph.D. in inorganic and analytical chemistry, and an MBA and a BSc in chemistry, each from Ben-Gurion University in Beer-Sheva, Israel.
Mr. Nir Sassi has been our Chief Financial Officer since August 2016. Prior to serving as our Chief Financial Officer, he served as our VP Finance commencing in March 2010. Prior to his service with us, Mr. Sassi served as a Senior Manager at PricewaterhouseCoopers Israel, an accounting firm, from 2002 until 2010, including two years relocation to the PricewaterhouseCoopers New York office. Mr. Sassi is a certified public accountant in Israel and has a bachelor’s degree in economics and accounting from Ben Gurion University in Beer Sheva, Israel.
R. Michael Gendreau, M.D., Ph.D.
Dr. R. Michael Gendreau was named as our Chief Medical Officer in February 2018. Prior to joining Intec, Dr. Gendreau founded a consulting firm providing strategic advice on the design and management of clinical programs, strategic planning, and technology assessments for emerging pharmaceutical, diagnostic, and medical device companies. He has served on various scientific advisory boards, executive strategic planning boards, and Data Safety Monitoring Boards. Prior to his consulting career, Dr. Gendreau served from 1996 until 2011 as Chief Medical Officer at Cypress Bioscience, Inc., a clinical-stage biotech company developing therapies for central nervous system disorders. Prior to Cypress Bioscience, Dr. Gendreau was Chief Medical Officer of Microprobe Corporation from 1991 to 1994. Additionally, he has served as Chief Medical Officer at other institutions including Battelle Memorial Institute. Dr. Gendreau received his B.S. in Chemistry from Ohio University, and earned his M.D./Ph.D. from The Ohio State University.
Walt A. Linscott
Mr. Linscott brings three decades of global leadership, entrepreneurial and professional experience with broad business development, operational, regulatory, and transactional experience in the Life Sciences sector. He is co-founder of a global consulting enterprise providing strategic advice to developing companies and has served as General Counsel and Corporate Secretary to public and private medical device and pharmaceutical companies including Cocrystal Pharma, Inc., Carestream Health, Inc. and Solvay Pharmaceuticals, Inc. where he also led compliance, IP, security, privacy, public affairs and government affairs functions. In addition, he was an associate and partner at Thompson Hine LLP for seventeen years collectively where he founded the firm’s Atlanta office, served as Partner in Charge and Chair of the firm’s Life Science Practice Group. Mr. Linscott holds a Postgraduate Diploma in Global Business from the University of Oxford and has recently completed a Postgraduate Diploma in Entrepreneurship from Cambridge University. He earned a Juris Doctor from the University of Dayton School of Law where he served as Managing Editor of the Law Review. After graduating with a bachelor’s degree from Syracuse University and prior to entering law school, he earned a commission and served on active duty as an Officer in the United States Marine Corps.